EYPT institutional options flow analysis — multi-leg block trades, dominant direction, and gamma analysis from the public options tape for April 13, 2026. Articles older than 60 days are public; a free account reads back to 30 days, Pro to 5, and AIme Premium reads today's unusual options trades with no delay.

AInvestOption Pilot Program
Unusual FlowDaily DigestEYPT Ticker Page

EYPT Unusual Options Activity — 2026-04-13

Institutional flow on 2026-04-13

Multi-leg block trades, dominant direction, and gamma analysis

$6.7M2 trades
CALENDAR PUT ROLL

Trade Details

BUY$10 PUT2026-10-16$4.0MCALENDAR PUT ROLL
SELL$10 PUT2026-08-21$2.7MCALENDAR PUT ROLL

Full Analysis

🛡️ EYPT $6.7M Calendar Put Roll - Smart Money Extending Downside Protection Into Phase 3 Readout!

📅 April 13, 2026 | 🔥 Unusual Activity Detected

🎯 The Quick Take

Someone just spent $6.7M rolling put protection on EYPT from August out to October, buying new $10 puts expiring October 2026 while closing the August position — a classic calendar put roll. With the make-or-break DURAVYU Phase 3 wet AMD data readout expected in mid-2026, this trader is paying up to keep downside protection active through the binary event window. Translation: Institutional money is making sure their insurance policy doesn't expire before the most important clinical trial result in the company's history.

📊 Company Overview

EyePoint, Inc. (EYPT) is a clinical-stage biopharmaceutical company focused on developing sustained-release treatments for serious retinal diseases:

  • Market Cap: $1.18B
  • Industry: Biotechnology / Pharmaceuticals
  • Exchange: NASDAQ
  • Current Price: $14.37
  • Primary Business: Developing DURAVYU (vorolanib) for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) using proprietary Durasert E sustained-release technology
  • Cash Runway: $306M, funding operations into Q4 2027

💰 The Option Flow Breakdown

The Tape (April 13, 2026):

| Time | Symbol | Buy/Sell | Type | Expiration | Premium | Strike | Volume | OI | Size | Spot | Option Price | Option Symbol | |------|--------|----------|------|------------|---------|--------|--------|----|----|------|------|--------------|---------------| | 13:32:57 | EYPT | BUY | PUT $10 | 2026-10-16 | $4M | $10 | 20,000 | 69 | 10,000 | $14.37 | $3.95 | EYPT20261016P10 | | 13:33:11 | EYPT | SELL | PUT $10 | 2026-08-21 | $2.7M | $10 | 22,000 | 10,000 | 10,000 | $14.37 | $2.70 | EYPT20260821P10 |

🤓 What This Actually Means

This is a textbook calendar put roll — two trades executed 14 seconds apart for exactly the same size and strike:

  • 💸 Leg 1 (BTO): Bought 10,000 contracts of the October 2026 $10 puts for $3.95 each = $4M total
  • 💰 Leg 2 (STC): Sold 10,000 contracts of the August 2026 $10 puts for $2.70 each = $2.7M collected
  • 📊 Net cost of the roll: $1.25/contract × 10,000 contracts = $1.25M net debit to extend protection
  • 🛡️ What they're protecting: $10 strike = protecting against EYPT falling below $10, roughly 30% downside from current price
  • ⏰ Why October: The DURAVYU Phase 3 wet AMD readouts (LUGANO and LUCIA trials) are expected in mid-2026. October expiration keeps the hedge alive through the entire data readout window and well into the post-data reaction period

The story here is straightforward: Someone who already held puts in EYPT was due to lose protection in August. Rather than let the hedge expire before the clinical trial results land, they paid $1.25M to push the protection out two more months to October. The $10 strike sits about 30% below current price, providing a floor on what is clearly a meaningful long equity position.

Unusual Score: 🔥 HIGH — 10,000 contracts against an open interest of just 69 on the October $10 strike means this trade created virtually all the open interest at that strike overnight. Volume was 290x the prior open interest for that specific option, which is the kind of footprint you'd expect from a single institutional actor establishing fresh protection.

📈 Technical Setup / Chart Check-Up

YTD Performance Chart

YTD Performance

EYPT has had a rough year so far. The stock traded as high as $18.85 over the past 52 weeks but has pulled back to the $14 area, down roughly 16% from its early January 2026 levels near $17.08. That decline reflects the tension between a compelling Phase 3 story and the reality that pre-commercial biotechs can bleed while investors wait for data. The stock is sitting above its 52-week low of $4.13 but nowhere near previous highs.

Key observations:

  • 📉 -16% from early 2026 highs near $17, reflecting data anticipation anxiety
  • 🎢 Wide 52-week range ($4.13 - $18.85) — this stock moves in big chunks based on clinical news
  • 📊 Elevated volume around the March 4, 2026 Q4 earnings report and corporate updates
  • ⚠️ $14 area acting as a current consolidation zone ahead of mid-2026 binary event

Gamma-Based Support & Resistance Analysis

Gamma S/R

Current Price: $14.37 — GEX Bias: Bullish

The gamma exposure map for EYPT is relatively straightforward given the stock's smaller options market:

🔵 Support Levels (Put Gamma Below Price):

  • $12.50 — The only notable support level, sitting 14.8% below current price. Total GEX at this strike is 0.033, which is modest but meaningful for a small-cap biotech. This is where put gamma could provide a natural cushion if selling pressure builds.

🟠 Resistance Levels (Call Gamma Above Price):

  • $15.00 — Immediate resistance just 2.2% above current price. Total GEX of 0.543 makes this the most gamma-heavy level on the board, and it's overhead. Dealers will hedge by selling into any rally toward $15, making this level sticky.
  • $17.50 — Secondary resistance 19.3% above current price. Less immediate, but a target if $15 breaks convincingly.

What this means for traders: EYPT is sandwiched between light $12.50 support and meaningful $15 resistance. The near-term path of least resistance is choppy sideways action until the clinical data changes the setup entirely. The $10 put strike from this trade sits well below both gamma levels — it's pure tail risk protection, not a play on gamma dynamics.

Net GEX Bias: Bullish (1.045B call gamma vs 0.431B put gamma) — dealer positioning leans bullish, but the actual catalyst that will move this stock has nothing to do with gamma levels.

Implied Move Analysis

Implied Move

Options market pricing for upcoming expirations:

  • 📅 Weekly / Monthly OPEX (April 17, 2026 — 4 days): ±$1.08 (±7.4%) → Range: $13.56 - $15.72

Translation for regular folks: Options traders are pricing in a 7.4% move by April 17 for the weekly/monthly OPEX. For a clinical-stage biotech, that's a meaningful but not extreme implied move — the market knows there's no major data event this week, so the vol is elevated from baseline uncertainty rather than a specific catalyst.

The key takeaway: the options market is acknowledging that EYPT is inherently volatile even between data events. That 7.4% weekly implied move is the everyday "ambient risk" baked into this stock. The real fireworks come when LUGANO topline data drops.

🎪 Catalysts

🔥 Upcoming Catalysts (Next 6 Months)

DURAVYU Phase 3 Wet AMD Readouts — Mid-2026 (THE BIG ONE) 📊

Per the January 7, 2026 corporate update, EYPT is expecting:

  • 🧪 LUGANO Trial: Topline data anticipated mid-2026 (estimated June-August 2026) — this is the first Phase 3 read on DURAVYU 2.7mg for wet AMD versus aflibercept (Eylea) with six-month redosing
  • 🧪 LUCIA Trial: Topline data expected shortly after LUGANO — identical trial design, second data point
  • 👥 Scale: 450+ patients enrolled per trial, 70-80% have received a second dose per Investing.com
  • ✅ Safety signal: Independent DSMC completed second scheduled review and recommended continuation with no protocol modifications

Q1 2026 Earnings (Expected May 2026)

  • Expected in May 2026 (date not yet confirmed)
  • Key metrics: cash burn rate, DME Phase 3 enrollment updates, any LUGANO/LUCIA enrollment notes

DME Phase 3 Program

  • First patient dosing in pivotal Phase 3 diabetic macular edema trials was expected in Q1 2026
  • DME topline data expected H2 2027 per MarketBeat
  • Adds pipeline depth beyond the wet AMD binary event

📋 Recent Catalysts (Already Happened)

Q4 & Full-Year 2025 Earnings — March 4, 2026

Per the GlobeNewsWire earnings release:

  • 💵 Q4 2025 revenue: $0.6M (down 94.8% YoY — mostly due to expiring license agreement, not operational deterioration)
  • 📉 Full-year 2025 net loss: $232M ($275M in operating expenses driven by Phase 3 program costs)
  • 💰 Cash position: $306M, extending runway into Q4 2027 per StockTitan

Analyst Activity

  • 📈 Citigroup raised target to $35 with Buy; Chardan raised to $29 with Buy following the March earnings
  • 📊 MarketBeat and TipRanks show 13 Buy / 0 Hold / 0 Sell consensus, median price target $33 (130% above current price)

Chief Commercial Officer Hire — February 18, 2026

  • EyePoint appointed Michael Campbell as CCO, signaling the company is preparing for potential DURAVYU commercialization per EyePoint Investor Relations

🎲 Price Targets & Probabilities

Based on gamma levels, implied move data, and the binary clinical catalyst:

🚀 Bull Case — $17.50 to $33+

  • Probability: ~40-50% (reflects analyst consensus and Phase 2 positive data)
  • Trigger: Positive LUGANO topline data showing DURAVYU meets non-inferiority vs Eylea
  • $15 gamma resistance would break decisively; $17.50 next gamma target; analyst median price target of $33 represents a fundamental re-rating
  • Timeline: Mid-2026 data readout

📊 Base Case — $12.50 to $15.00

  • Probability: ~25-30%
  • Scenario: Continued sideways drift as investors wait for data; some trial delay or mixed interim signals
  • Stock likely range-bound between $12.50 gamma support and $15 gamma resistance

😰 Bear Case — Below $10

  • Probability: ~20-25% (this is what the $10 put protects against)
  • Trigger: Failed Phase 3 readout — DURAVYU does not achieve non-inferiority against Eylea
  • Per the EYPT catalyst research, a failed trial could send shares below $5 given the company's pre-commercial status
  • The $10 put provides significant protection in this scenario: each $1 EYPT falls below $10, the put gains $1 per share (×100 per contract ×10,000 contracts)

💡 Trading Ideas

🛡️ Conservative — "The Safety Net Play"

Long stock with defined downside via OTM puts

  • Buy EYPT stock at ~$14.37
  • Buy October 2026 $10 puts for ~$3.95
  • Total cost basis: ~$18.32 per share
  • Max loss: $8.32 per share (if stock goes to zero)
  • Why this works: You participate in the upside if DURAVYU data is positive while limiting downside to a defined level

⚖️ Balanced — "The Straddle Setup"

Buy both calls and puts ahead of the binary event

  • Consider an at-the-money straddle on a shorter expiration ahead of the LUGANO data readout (June-July)
  • Buy June or July $14 call and $14 put
  • Profit on a big move in either direction — which is exactly what a Phase 3 binary event produces
  • Why this works: Phase 3 readouts in biotech regularly produce 30-50% moves; a straddle profits from the move regardless of direction

🚀 Aggressive — "Ride the Upside"

Out-of-the-money call spreads targeting a positive readout

  • Buy August 2026 $15/$20 call spread (buy $15 call, sell $20 call)
  • Defined risk, defined reward — profit if the data is positive and stock rallies toward analyst targets
  • Why this works: Leveraged upside exposure at lower cost than outright calls; risk is capped at premium paid

⚠️ Risk Factors

Clinical Execution Risk: The DURAVYU Phase 3 readout is a binary event. Non-inferiority trials can fail even with promising Phase 2 data. If LUGANO doesn't meet endpoints, the stock could fall sharply — potentially to $5 or below given the company has no meaningful commercial revenue.

Cash Burn: Per the Q4 2025 earnings, EYPT burned $275M in FY2025. The $306M cash position funds through Q4 2027, but any trial failure would likely require dilutive equity raises.

Competitive Threats: Gene therapies (ixo-vec, 4D-150) in Phase 3 for wet AMD, plus biosimilar Eylea entrants, could erode DURAVYU's market opportunity even if the drug succeeds clinically. Per the American Academy of Ophthalmology, the anti-VEGF market is well-established with multiple competing approaches.

Time Decay on the Puts: At $3.95 for the October $10 put, the holder is paying a meaningful premium relative to the stock price. If LUGANO data arrives in June or July and is positive, those puts will likely expire worthless — losing the full $4M paid for the new leg.

Regulatory Risk: Even positive Phase 3 data requires FDA review (12-18 months post-data) and successful manufacturing scale-up of Durasert E technology, per HC Wainwright's March 2026 analysis.

🎯 The Bottom Line

Real talk: This calendar put roll is essentially a very well-capitalized investor saying "I believe in the DURAVYU story, but I'm not going to be unprotected if the Phase 3 data misses." They already held August puts, and rather than let that hedge expire before the data, they paid $1.25M more to keep the insurance active through October.

What's notable is what this trade is NOT: it's not a directional bearish bet. If it were, they'd just buy new puts without selling the August ones. The roll structure tells you this is portfolio protection, not speculation — they're managing a long position.

Three scenarios:

  • 📈 If you own EYPT or are bullish: The whale is doing what smart long holders do — staying long while buying insurance. The unanimous Buy consensus with $33 median target reflects genuine conviction in DURAVYU's platform.
  • 👀 If you're watching from the sidelines: The mid-2026 data window is the setup. Any meaningful pullback before the LUGANO readout could be an entry point for traders who want to own the binary catalyst at a lower cost basis.
  • 📉 If you're bearish: The $10 put structure already prices in significant downside. A failed trial could push EYPT well below $10, but the options market is pricing that risk — puts at $3.95 with the stock at $14.37 is not cheap protection.

Mark your calendar for mid-2026 — specifically the June-August window when LUGANO topline data is expected. That single readout will define this company's value for years to come.

⚠️ Options trading involves substantial risk and is not suitable for all investors. Options can expire worthless, resulting in a total loss of premium paid. This analysis is for educational purposes only and does not constitute investment advice. Past unusual activity does not guarantee future performance. Always consult a licensed financial advisor before making investment decisions.

The Options Desk tracks the move options price into every US earnings report the week of Sep 7, next to how much each stock has actually moved on its past prints — plus the SPY, QQQ and IWM expected ranges and the gamma walls that box them in.